Evidence map›Paper›PMID 29577081›Full record

ArticleInternational journal of HIV/AIDS and research2017

Pharmacogenetic Associations with ADME Variants and Virologic Response to an Initial HAART Regimen in HIV-Infected Women.

C L Pearce, D Stram, A Wiensch, M A Frasco, N Kono, D V Den Berg, K Anastos, M H Cohen, J DeHovitz, E T Golub and 3 more

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of HIV/AIDS and research, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 85% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 2 institutions in 1 country.

C L PearceDepartment of Epidemiology, University of Michigan School of Public Health, Ann Arbor, MI, USA.
D StramDepartment of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.
A WienschDepartment of Epidemiology, University of Michigan School of Public Health, Ann Arbor, MI, USA.
M A FrascoDepartment of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.
N KonoDepartment of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.
D V Den BergDepartment of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.
K AnastosDepartment of Medicine, Montefiore Medical Center and Albert Einstein College of Medicine, Bronx, NY, USA.
M H CohenDepartments of Medicine, Stroger Hospital and Rush University, Chicago, IL, USA.
J DeHovitzDepartment of Medicine and Community Health, SUNY Health Sciences Center, Brooklyn, NY, USA.
E T GolubDepartment of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.
B TamrazDepartment of Clinical Pharmacy, University of California, School of Pharmacy, San Francisco, CA, USA.
C LiuDepartment of Medicine, Georgetown University School of Medicine, USA.
W J MackDepartment of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.
University of Michigan–Ann Arbor · USUniversity of Southern California · US

Funding

Engaging University of California Stakeholders for Biorespository ResearchUL1TR000004 · NCATS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI GRANDIS, JENNIFER RUBIN · 2012 to 2015
$78.0M
Women's Interagency HIV Study (WIHS-V)U01AI035004 · NIAID · MONTEFIORE MEDICAL CENTER (BRONX, NY) · PI ANASTOS, KATHRYN M., SHARMA, ANJALI · 1993 to 2018
$65.7M
WOMEN'S INTERAGENCY HIV STUDY ORGANIZATION, MANAGEMENT AND COMMUNICATIONSU01AI034989 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI AOUIZERAT, BRADLEY E, GREENBLATT, RUTH MARTHA · 1993 to 2018
$65.6M
Women's Interagency HIV Study (WIHS) IIIU01AI031834 · NIAID · SUNY DOWNSTATE MEDICAL CENTER · PI GUSTAFSON, DEBORAH R., MINKOFF, HOWARD · 1998 to 2018
$53.5M
WOMEN'S INTERAGENCY HIV STUDY (WIHS) ORGANIZATION AND MANAGEMENTU01AI034994 · NIAID · GEORGETOWN UNIVERSITY · PI KASSAYE, SEBLE G · 1993 to 2018
$52.0M
Women's Interagency HIV Study (WIHS) IV, Chicago ConsortiumU01AI034993 · NIAID · HEKTOEN INSTITUTE FOR MEDICAL RESEARCH · PI COHEN, MARDGE H, FRENCH, AUDREY · 1994 to 2018
$51.0M
WOMENS INTERAGENCY HIV STUDY (WIHS)U01HD032632 · NICHD · UNIVERSITY OF SOUTHERN CALIFORNIA · PI MILAM, JOEL E · 1994 to 2012
$42.0M
WIHS DATA MANAGEMENT AND ANALYSIS CENTER(WDMAC)U01AI042590 · NIAID · JOHNS HOPKINS UNIVERSITY · PI GANGE, STEPHEN J, GOLUB, ELIZABETH T · 1998 to 2018
$38.4M
Atlanta Clinical and Translational Science Institute (ACTSI) RenewalUL1TR000454 · NCATS · EMORY UNIVERSITY · PI STEPHENS, DAVID S · 2012 to 2016
$25.8M
Emory WIHS CRS - Longitudinal CohortU01AI103408 · NIAID · EMORY UNIVERSITY · PI OFOTOKUN, IGHOVWERHA, WINGOOD, GINA MARIA · 2013 to 2018
$14.1M
UAB-MISS WIHS CohortU01AI103401 · NIAID · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI KEMPF, MIRJAM-COLETTE, KONKLE-PARKER, DEBORAH J · 2013 to 2018
$11.2M
University of North Carolina Womens Interagency HIV Study UNC WIHSU01AI103390 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI ADIMORA, ADAORA A · 2013 to 2018
$11.0M
NIAID NIH HHS U01 AI031834NIAID NIH HHS U01 AI034989NIAID NIH HHS U01 AI034993NIAID NIH HHS U01 AI034994NIAID NIH HHS U01 AI035004NIAID NIH HHS U01 AI042590NIAID NIH HHS U01 AI103390NIAID NIH HHS U01 AI103397NIAID NIH HHS U01 AI103401NIAID NIH HHS U01 AI103408NICHD NIH HHS U01 HD032632
6 · The paper itself

Abstract

backgroundClinical response to highly active antiretroviral therapy (HAART) varies among different populations. A portion of this variability may be due to variation in genes involved in the absorption, distribution, metabolism, and excretion (ADME) of HAART.

designTo identify genetic factors involved in virologic responses to HAART, 13 genes in ADME pathways were analyzed in a cohort of HIV-infected women on HAART. A total of 569 HIV-positive participants from the Women's Interagency HIV Study who initiated HAART from 1994-2012 and had genotype data were included in these analyses.

methodsAdmixture maximum likelihood burden testing was used to evaluate gene-level associations between common genetic variation and virologic response (achieving <80 viral copies/mL) to HAART overall and with specific drug classes. Results: Six statistically significant (P<0.05) gene-level burden tests were observed with response to specific regimen types.

conclusionsAlthough no genome-wide associations with virologic response to HAART overall were detected in this cohort of HIV-infected women, more statistically significant gene-level burden tests were observed than would be expected by chance (two and a half expected, six observed). It is likely that variation in one of the significant genes is associated with virologic response to certain HAART regimens. Further characterization of the genes associated with response to PI-based treatment is warranted.

Indexed as

ADMEHAARTHIVPharmacogenomicsWomen

Identifiers

PMID29577081
PMCPMC5863915
OpenAlexW2765658153

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.